News

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
"Sapo": Psychedelics. "The risk of the person becoming dependent on the substance used in the treatment is very low"
Ketamine, which has antidepressant and anxiolytic properties, is predominantly used, with solid scientific evidence collected over the last few decades.
17/05/2023
"Marie Claire": I used ketamine to treat depression and regained my will to live.
Anesthetic is indicated for cases resistant to conventional remedies.
19/03/2023
"European Medicines Agency": A second chance for psychedelics
The European Medicines Agency recognizes that psychedelic-assisted therapy is promising for dealing with various mental health conditions.
16/03/2023
"Financial Times": US clinic offers ketamine therapy to treat alcoholism.
Awakn, a British biotechnology company, licenses medicine for addiction treatment clinics.
14/03/2023
"Psychedelic Health": Ketamine for alcohol dependence receives UK Innovation Passport
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has awarded Awakn Life Sciences an Innovation Passport for its patented Ketamine-Assisted Psychotherapy for the treatment of Severe Alcohol Use Disorder.
7/02/2023
"The Economist": Five stories that will change the world in 2023 - Psychedelic medicine
There are three psychedelic drugs already in the advanced stages of clinical trials for the treatment of mental health that could become part of our prescriptions. One of them is ketamine.
27/12/2022
"BBC": Clinical trial of Ketamine for alcohol dependence moves to next stage in UK
The clinical trial led by the University of Exeter and Awakn Life Sciences, with funding of 2.4 million pounds, will take place in seven NHS centers across the UK.
13/12/2022
"The Economist": Ketamine, psilocybin and ecstasy are making their way into the medicine cabinet.
From expanding minds to healing brains.
21/09/2022